Breaks Categories: Stock Spotlights

ThursdayFeb 09, 2017 11:44 am

NetworkNewsBreaks – Investors Applaud Marchex’s (NASDAQ: MCHX) Partnership with Facebook (NASDAQ: FB) to Launch Omnichannel Analytics Cloud; Shares Higher

Shares of Marchex (NASDAQ: MCHX) are up 16% after the mobile advertising analytics company announced its partnership with Facebook (NASDAQ: FB) that will integrate across its social analytics solution and into an industry-leading analytics platform called the Marchex Omnichannel Analytics Cloud. The integrated technology is designed to help marketers connect offline customer behavior to online marketing activity. “Online advertising has long struggled to connect digital engagements with accurate attribution to offline interactions and sales. While the influence of mobile phones and reach of digital channels like Facebook is undeniable, we also know that a large portion of sales are still…

Continue Reading

WednesdayFeb 08, 2017 12:05 pm

NetworkNewsBreaks – Cellect Biotechnology (NASDAQ: APOP) Treats First Cancer Patient In Phase I/II Trial of ApoGraft™; Shares Surge

Cellect Biotechnology (NASDAQ: APOP) is trading 26% higher mid-morning following word the company has treated the first blood cancer patient in the recently initiated phase I/II trial of its stem cell technology ApoGraft™. The intent of the trial is to assess the Cellect ApoGraft™ process which is designed to prevent Graft-versus-Host Disease (GvHD), a common complication linked to stem cell transplant. Additionally, the company expects to release definitive and complete results of its trial on healthy volunteers before the end of the first quarter this year. “Enrolling our first cancer patient to be treated using our groundbreaking method is a…

Continue Reading

TuesdayFeb 07, 2017 12:38 pm

NetworkNewsBreaks – Iao Kun Group Holding Company Ltd. (NASDAQ: IKGH) Enters Chinese Technology Industry with Majority Stake in LiNiu Network

Iao Kun Group (NASDAQ: IKGH) this morning said its strategy to focus on the Chinese technology industry begins with its acquisition of a 51% interest in Jia-Heng Industrial Ltd., the holding company of Guangzhou LiNiu Network Technology Co. Ltd., a software technology development company that's developing an electronic B2C trading platform focused on the Chinese agricultural industry. Per the agreement, IKGH will issue 12.484 million ordinary shares upon the transaction’s closing, as well as cash consideration that is contingent upon LiNiu Network achieving after-tax income targets. The acquisition is expected to close in the first quarter of 2017. “After appropriate…

Continue Reading

TuesdayFeb 07, 2017 12:36 pm

NetworkNewsBreaks – Israel’s B.O.S. (NASDAQ: BOSC) Hits “Significant Milestone” with $380,000 Order from American Customer

B.O.S. Better Online Solutions ("BOS") (NASDAQ: BOSC) is trading higher after the RFID and mobile solutions provider said its Supply Chain Division has received an electronic components order from an American customer valued at $380,000. The order is anticipated to be delivered in the first quarter of 2017. “This order marks a significant milestone in our sales to the American market, as we expect it to be followed by additional orders from this customer,” BOS president Avidan Zelicovski stated in the news release. BOS is scheduled to release its fourth-quarter and fiscal year results on March 21. To view the…

Continue Reading

TuesdayFeb 07, 2017 12:34 pm

NetworkNewsBreaks – VBI Vaccines, Inc. (NASDAQ: VBIV) Trades Higher on Positive Scientific Advice from EMA

VBI Vaccines (NASDAQ: VBIV) ("VBI") this morning said it has received positive scientific advice regarding its European development path for its Sci-B-Vac™ vaccine from the European Medical Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). In its letter, the CHMP stated its support of VBI's proposed plan to proceed to the phase III clinical studies of Sci-B-Vac™, and agreed that the product information and data from ongoing studies supports the phase III clinical studies and VBI's planned filing of a market authorization application. The company is also evaluating plans for the pivotal phase III clinical studies with the…

Continue Reading

MondayFeb 06, 2017 1:17 pm

NetworkNewsBreaks – Aytu Bioscience, Inc.’s (AYTU) MiOXSYS® Platform Addresses Diagnostic Challenges of Male Infertility

Oxidative stress is known to be a contributing factor to male infertility, though a significant amount of infertility cases remain unexplained. This is largely due to a lack of standardized tests to determine oxidative stress. A new clinical application called MiOXSYS®, however, is set to change that by assessing oxidative stress levels in semen as an aid in the diagnosis of male infertility. The platform is being developed by Aytu BioScience (OTCQX: AYTU), a leading pharmaceutical company focusing on the commercialization of innovative urology products. The company is currently pursuing regulatory approval for commercialization in the United States while boosting…

Continue Reading

MondayFeb 06, 2017 1:15 pm

NetworkNewsBreaks – Newtek Business Services Corp. (NASDAQ: NEWT) Embraces E-Commerce as Growing Payment Trend

As a business development company, Newtek Business Services (NASDAQ: NEWT) is focused on providing financial and business services to the small- and medium-sized business market. Through its electronic payment processing, managed technology solutions, small business finance, and Capcos segments, Newtek has helped increase revenues, reduce expenses and minimize risks for over 100,000 business accounts. Newtek’s electronic payment and eCommerce solutions portfolio companies processed $4.7 million in sales for its eCommerce merchants on Black Friday 2016, a substantial 12.6% increase over Black Friday the year prior. To learn more, visit www.newtekone.com About Newtek Business Services Corp. Newtek Business Services Corp., Your…

Continue Reading

MondayFeb 06, 2017 11:20 am

NetworkNewsBreaks – FDA Grants Small Business Status to Cytori (NASDAQ: CYTX)

Cytori (NASDAQ: CYTX) has been granted Small Business status for fiscal year 2017 by the U.S. Food and Drug Administration Division of Industry and Consumer Education. The designation allows Cytori to receive substantial financial incentives, fee reductions, and fee waivers for selective FDA medical device regulatory filings. The company is also eligible for a substantial reduction in many medical device user fees and a one-time waiver of the user fee for its first premarket approval (PMA) application, potentially occurring later in 2017. “Cytori Cell Therapy benefits from being regulated as a device through the PMA process. The small business designation…

Continue Reading

MondayFeb 06, 2017 11:15 am

NetworkNewsBreaks – Rosetta Genomics (NASDAQ: ROSG) Receives Two U.S. Patent Allowances for RosettaGx Reveal™ microRNAs

Rosetta Genomics (NASDAQ: ROSG) shares are nudging higher after the company said the U.S. Patents and Trademark Office has granted two patent allowances for divisional patents of the parent application titled “microRNAs and uses thereof.” The company said the patents are important markers for its RosettaGX Reveal™ thyroid cancer assay, as this strengthens its intellectual property portfolio and provides opportunities for monetization. “We are creating a strong intellectual property position in microRNAs and thyroid cancer diagnostics. Of note, there are approximately 500 peer-reviewed publications that confirm the effectiveness of microRNAs as biomarkers in the diagnosis of thyroid cancer which makes…

Continue Reading

FridayFeb 03, 2017 3:44 pm

NetworkNewsBreaks – Soligenix, Inc.’s (NASDAQ: SNGX) SGX301 Receives Promising Innovative Medicine Designation in the UK; Aegis Capital Increases PT to $7

Shares of Soligenix (NASDAQ: SNGX) continued to climb Friday following the company’s announcement yesterday that its SGX301 was granted Promising Innovative Medicine (PIM) designation in the United Kingdom by the Medicines and Healthcare Products Regulatory Agency for the treatment of cutaneous T-cell lymphoma. The PIM designation is the first step toward inclusion in the Early Access to Medicines Scheme (EAMS), which provides severely ill patients with life-threatening and seriously debilitating conditions early access to groundbreaking new medicines - before marketing authorization is approved. "This is now the second of our programs to receive this important designation, with the first being…

Continue Reading